Mediaspace scheduled maintenance: Aug 25, 2026 07:00 - 12:00 AM. During this time, videos will be temporarily unavailable. Check status updates.

Recherche

Afficher tous les résultats pour

Accueil

Personne

Myriam Briki

À propos
Confidentialité
Mentions légales

Graph Chatbot

Publications associées (4)

Page 1 sur 1

Sustained viral suppression with once daily dolutegravir-containing regimen in presence of the strong inducer carbamazepine

Myriam Briki

Dolutegravir 50 mg twice daily (BID) dosing is currently recommended in presence of strong inducers of drug metabolism. However, this dosing has been challenged by studies showing similar rates of viral suppression with dolutegravir once daily (QD) compare ...

SAGE PUBLICATIONS LTD2025

Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A Perspective

Sandro Carrara, Myriam Briki

Therapeutic drug monitoring (TDM) of conventional cytotoxic chemotherapies is strongly supported yet poorly implemented in daily practice in hospitals. Analytical methods for the quantification of cytotoxic drugs are instead widely presented in the scienti ...

MDPI2023

Population pharmacokinetics of bictegravir in real-world people with HIV

Myriam Briki

Objectives Bictegravir is an integrase strand transfer inhibitor widely prescribed due to its good efficacy and safety profile. Its pharmacokinetic (PK) profile has not been described in real-world settings yet. This study aimed to characterize bictegravir ...

Oxford University Press (OUP)2025

Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) methods for the therapeutic drug monitoring of cytotoxic anticancer drugs: An update

Sandro Carrara, Myriam Briki

In the era of precision medicine, there is increasing evidence that conventional cytotoxic agents may be suitable candidates for therapeutic drug monitoring (TDM)- guided drug dosage adjustments and patient's tailored personalization of non-selective chemo ...

Elsevier2024